Naproxen immediate-release - Oxford Pharmascience

Drug Profile

Naproxen immediate-release - Oxford Pharmascience

Alternative Names: Gastric-safe naproxen; Immediate release naproxen - Oxford Pharmasciences; OXP 005; OXPzero™ naproxen

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford Pharmascience
  • Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Musculoskeletal pain

Most Recent Events

  • 27 Sep 2017 Suspended - Phase-I for Musculoskeletal pain (In volunteers) in United Kingdom, pending conclusion of a strategic review (PO)
  • 09 Nov 2016 Oxford Pharmascience's naproxen immediate-release is available for market licensing as of 09 Nov 2016. www.oxfordpharmascience.com
  • 09 Nov 2016 Oxford Pharmascience files for patent protection with UK Intellectual Property Office for OXPzero™ technology in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top